RCS - Seed Innovations Ltd - Investee Company Update: Little Green Pharma Ltd

Seed InnovationsAnnouncement

07/09/2023 10:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230907:nRSG7390La&default-theme=true

RNS Number : 7390L  Seed Innovations Limited  07 September 2023

7 September 2023

 

SEED Innovations Limited

 

("SEED" or the "Company")

 

Investee Company Update: Little Green Pharma Ltd

 

SEED Innovations Ltd, the AIM-quoted company investment company providing
shareholders with exposure to early-stage health, wellness and medical
cannabis companies to which, in normal circumstances, they have limited access
to, is pleased to note an announcement released on the ASX by its portfolio
company, Little Green Pharma Ltd ('LGP').

 

The Company owns 7,324,796 ordinary shares in LGP representing 2.44% of LGP's
issued share capital.

The following announcement, which was released on the ASX is set out without
any material changes.

 

Large Scale Cannabis Study Findings Released

Results find medicinal cannabis significantly improves pain, quality of life
& fatigue.

Little Green Pharma (ASX: LGP) wishes to advise of a media release issued
today relating to the analysis of the initial three month results from the
QUEST Initiative 1  . A copy of that media release is appended to this link:
https://investor.littlegreenpharma.com/site/pdf/f8a54588-1827-47b7-a13e-499fc99d6909/Large-scale-cannabis-study-findings-released.pdf
(https://investor.littlegreenpharma.com/site/pdf/f8a54588-1827-47b7-a13e-499fc99d6909/Large-scale-cannabis-study-findings-released.pdf)
 

Analysis of the initial three-month follow-up results from 2,327 Australian
patients participating in the QUEST Initiative show:

·    very strong evidence of clinically meaningful improvements for those
suffering health-related quality of life (HRQL) and fatigue

·    clinically meaningful reductions in pain and significant improvements
for moderate-severe anxiety and depression

Analysis of 12-month results is currently being undertaken to see if such
improvements are maintained over the longer term.

Overview

The QUEST Initiative, sponsored by LGP, was one of the world's largest
longitudinal clinical studies investigating the effect of medicinal cannabis
on patient quality of life and health economic impacts. The study was led by a
leading Australian university with LGP exclusively supplying the medicinal
cannabis products to patients enrolled in the study and with Study costs fully
funded from patient participation fees. The study was also supported by
not-for-profit private health insurance provider Health Insurance Fund of
Australia (HIF) and guided by an experienced advisory group and endorsed by a
range of national bodies, such as MS research Australia, Chronic Pain
Australia, Arthritis Australia and Epilepsy Australia. For a full analysis of
the results, please refer to the link attached.

The announcement in full can be accessed from the following link:
https://investor.littlegreenpharma.com/site/pdf/f8a54588-1827-47b7-a13e-499fc99d6909/Large-scale-cannabis-study-findings-released.pdf
(https://investor.littlegreenpharma.com/site/pdf/f8a54588-1827-47b7-a13e-499fc99d6909/Large-scale-cannabis-study-findings-released.pdf)

- Ends -

For further information on the Company please
visit:    www.seedinnovations.co (http://www.seedinnovations.com/)
     or contact:

 

  Ed McDermott        SEED Innovations Ltd             E: info@seedinnovations.co 

 Lance de Jersey                                        
 James Biddle         Beaumont Cornish Limited,        T: (0)20 7628 3396

 Roland Cornish       Nomad                             
 Isabella Pierre      Shard Capital Partners LLP       T: (0)20 7186 9927

 Damon Heath          Broker
 Catherine Leftley    St Brides Partners Ltd,          E: info@stbridespartners.co.uk

 Ana Ribeiro          Financial PR

 Isabelle Morris

 

 

Notes

 

Seed Innovations Ltd

 

SEED Innovations is an AIM quoted investment company focused primarily on
disruptive high growth life sciences and technology businesses particularly
within the medical cannabis arena. The Company's strategy is to identify
early-stage opportunities that have an upcoming investment catalyst and grow
its portfolio in terms of value whilst limiting the number of investee
companies to a level where relevant time can be devoted to each.

 

 

About Little Green Pharma

 

Little Green Pharma is a global, vertically integrated and geographically
diverse medicinal cannabis business with operations from cultivation and
production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its
own-branded and white-label ranges of GMP-grade medicinal cannabis products,
being a 21,500m2 cultivation and 4,000m2 GMP manufacturing facility capable of
producing over 30 tonnes of medicinal cannabis biomass per annum located in
Denmark (EU) and an indoor cultivation and manufacturing facility located in
Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass
per annum.

 

Little Green Pharma products comply with all required Danish Medicines Agency
and Therapeutic Goods Administration regulations and testing requirements.
With a growing range of products containing differing ratios of active
ingredients, Little Green Pharma supplies medical-grade cannabis products to
Australian, European and overseas markets.

 

The Company has a strong focus on patient access in the emerging global
medicinal cannabis market and is actively engaged in promoting education and
outreach programs, as well as participating in clinical investigations and
research projects to develop innovative new delivery systems.

 

 1  Refer to ASX announcement dated 18 February 2021.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPUQWBUPWUBM